

Available online at www.sciencedirect.com



GENOMICS

Genomics 90 (2007) 746-750

www.elsevier.com/locate/ygeno

Brief Communication

Can probability of genetic mutation be an indicator of clinical relevance?

Chien-Lun Chen^{a,b}, Ke-Hung Tsui^a, Chiao-Yun Lin^c, Phei-Lang Chang^a, Petrus Tang^c, Benjamin Yat-Ming Yung^{d,*}

^a Department of Urology, Chang Gung Memorial Hospital, Chang Gung Bioinformatics Center, Kwei-Shan, Tao-Yuan 333, Taiwan, Republic of China

^b Graduate Institute of Clinical Medical Sciences, College of Medicine, Kwei-Shan, Tao-Yuan 333, Taiwan, Republic of China

^c Department of Parasitology, Chang Gung Bioinformatics Center, Kwei-Shan, Tao-Yuan 333, Taiwan, Republic of China

^d Department of Pharmacology, College of Medicine, Chang Gung University, Kwei-Shan, Tao-Yuan 333, Taiwan, Republic of China

Received 30 May 2007; accepted 11 July 2007 Available online 24 October 2007

Abstract

NPM1 gene mutation evaluated on a population basis is a valuable and realistic tool to reflect the pathophysiological relevance of cancer. In a comparison of the *NPM1* cDNA of human bladder cancer with its consensus sequence, we have found that a higher *NPM1* sequence identity in a population is consistent with poor tumor differentiation, advanced tumor stage, and likelihood of recurrence. These data imply that "probability" of *NPM1* mutation is an indicator of status of malignancy.

© 2007 Elsevier Inc. All rights reserved.

Keywords: Nucleophosmin; Population genetics; Probability of mutation; Genetic variations; Gene identity

Genetic variations in the human genome range from a single nucleotide to megabases in size. While copy number variations (CNVs) are widely seen in human cancers [1-5], single-nucleotide polymorphisms (SNPs) may also play a role in individual disease susceptibility [6]. Unlike the association of CNVs with phenotype change, accumulation of nucleotide changes in a gene in a population has not been well delineated.

Nucleophosmin (NPM; also known as B23, NO38, or numatrin) is a multifunctional nucleolar phosphoprotein. NPM has crucial roles in proliferation and homeostasis, such as ribosome biogenesis, centrosome duplication, cell cycle progression, and cell differentiation [7,8].

NPM is important in apoptosis and modulation of the ARF– p53 tumor suppressor pathway [9]. With the intriguing biological function as an oncogene or a tumor suppressor, the gene dosage, expression level, and genetic mutation of *NPM1* have been examined extensively [10].

In hematological malignancy, *NPM1* translocations and the resulting fusion proteins are often found. Patients with anaplastic large cell lymphoma (ALCL) with *NPM1/ALK* t(2;5)(p23;q35)

* Corresponding author. Fax: +886 3 2118615. *E-mail address:* byung@mail.cgu.edu.tw (B. Yat-Ming Yung) translocation show excellent response to induction therapy and are prone to better prognosis [11]. *NPM1* exon 12 and cyto-plasmic NPM mutant (NPMc⁺) in acute myelogenous leukemia

Table 1 Patient characteristics

	No.	%
Patients	43	
Patient age (years)		
Median	69	
Range	35-90	
Sex		
Male	33	76.7
Female	10	23.3
T stage		
pT1	29	67.4
pT2	5	11.6
pT3	8	18.6
pT4	1	2.3
Histologic grade		
1	15	34.8
2	18	41.9
3	10	23.3
Primary tumor	26	60.5
Recurrent tumor	17	39.5

(AML) represent subgroups with better treatment response and prognosis [12,13]. The genetics underlying the pathogenesis of solid tumor, however, is poorly defined.

Over 90% of bladder cancers are transitional cell carcinomas that have recurrence rates as high as 50-70%. About 20% of recurrences progress to invasive cancer. Metastatic bladder cancer is incurable and associated with poor prognosis. Dyrskjot et al. have reported the molecular signature of superficial bladder cancer with a propensity for invasion [14]. The majority of these genes are involved in the regulation of apoptosis, cell differentiation, and cell cycle progression. We previously have shown that NPM mRNA overexpression is associated with advanced tumor stages and grades [15]. This prompts us to investigate the possible NPM1 genetic correlation with its clinical relevance. Since an event of cancerous transformation is the final result of multiple deregulations, a single genetic change may not be enough to reflect to phenotype. It thus becomes conceivable and important for us to evaluate genetic changes in NPM1 on a population basis.

Results

With the approval of the Institutional Review Board for the Protection of Human Subjects, 43 patients with bladder transitional cell carcinoma diagnosed from 2002 to 2004 at Chang Gung Memorial Hospital were recruited. Patients' ages ranged from 35 to 90 years (median 69). Thirty-three (76.7%) patients were male and 10 (23.3%) were female. Twenty-six (60.5%) patients had primary and 17 (39.5%) had recurrent bladder cancers. The pathological grading was 15 (34.8%) grade 1, 18 (41.9%) grade 2, and 8 (23.3%) grade 3 tumor. Twenty-nine (67.4%) patients were pT1, 5 (11.6%) were pT2, 8 (18.6%) were pT3, and 1 (2.3%) was pT4 stage (Table 1).

Tumors with similar pathological or clinical setting were segregated for alignment to the consensus RefSeq cDNA sequence of *NPM1*. With the algorithm of ClustalW applied in the alignment analysis of vector NTI, the gene identity was quantified. Fig. 1 shows the complexity of *NPM1* in each population. The shaggy appearance at the end of each bar denotes the variation in the population alignment (Fig. 1A).




Fig. 1. *NPM1* population alignment. (A) *NPM1* complexity in different clinicopathological settings. Bladder tumors of pathological superficial stage (T1), invasive stage (T2–4), histological grade (G1, G2, G3), and primary (P) or recurrent (R) are assorted for alignment. Sample number in each group is shown in Table 1. p and s, start and end of cloned sequences; q and r, start and end of alignment to consensus *NPM1* cDNA. (B) *NPM1* alignment at the C_terminus. The top shows tumors of pathological stage T1 and the bottom those of advanced stages (T2–T4). At the top of each group is the consensus *NPM1* sequence. Yellow color denotes identical alignment in all specimens. α , arbitrary sample names; β , clinical/pathological information; γ , group alignment.

P

В										
(868)	868	380	890	900	910 9	20	930	940	950	964
B23 Exon-cDNA 885 bp (791)	TGGAAGCCAAAT	CATCAATT	ATGTGAAGAAT	TGC <mark>T</mark> T <mark>C</mark> CGG <mark>A</mark>	TGACTGAC <mark>C</mark> AA	GAGGCTATT	AAGATCT-	CTGGCAGT <mark>G</mark> -G	-AGGAA <mark>G</mark> TC <mark>T</mark>	CTTTA
D6_1151-F_147H03#A59-T1G3P (833)	TGGAAGCCAAAT	r <mark>catca</mark> att <mark>/</mark>	<mark>AT</mark> GTGAAGAAT	TGC <mark>T</mark> TCGG-A	TGACTGAC <mark>C</mark> A-	GAGGCTATT	AAGATCTT	CTGGCAGT <mark>G</mark> -G	- <mark>AGGAA</mark> GTC <mark>T</mark>	CTTTA
A36T_1151F_083H05#A36-T1G2P (826)	TGGAAGCCAATT	- <mark>CATCA</mark> ATT <mark></mark>	AT <mark>GTGAAGAT</mark> T	GCT <mark>TTCCGG</mark> A	TGACTGAC <mark>C</mark> AG	A <mark>AG</mark> CTATT	AGAATCT-	CTG <mark>GCAGT</mark> G	G <mark>AGGAA</mark> GTC <mark>T</mark>	CTTTA
A2_1151-F_147E01#4-T1G1P (829)	TGGAAGCCA <mark>A</mark> AT	r <mark>catca</mark> att <mark>/</mark>	<mark>AT</mark> GTGAAGAAT	TGC <mark>T</mark> T <mark>C</mark> CG- <mark>A</mark>	TGACTGAC <mark>C</mark> A-	GAGGCTATT(A-GATCT-C	CTGGCAGT <mark>G</mark> -G	- AGGAA <mark>G</mark> TC <mark>T</mark>	CTTTA
B2_1151-F_147F01#A4-T1G2P (840)	TGGAAGCCAAAT	- <mark>CATCA T</mark> 7	AT <mark>GTGAAGAA -</mark>	TGC <mark>T</mark> T <mark>C</mark> CGG <mark>A</mark>	TGACTGAC <mark>C</mark> A-	GAGGCTATT(A-GATCT-C	CTGGCAGT <mark>G</mark> -G	- AGGAA <mark>G</mark> TC <mark>T</mark>	CTTTA
A1_1151-F_147A01#3-T1G1P (815)	TGGAAGCCAAT-	-CATCAAT-	AT - TGAG <mark>GA</mark>	TGC <mark>T</mark> T <mark>C</mark> CG- <mark>A</mark>	TGACTGAC <mark>C</mark> A-	GAGGCTATT	T <mark>A-<mark>G</mark>ATCT-(</mark>	CTGGC-GT <mark>G</mark> -G	- <mark>AGGAA</mark> GT - <mark>T</mark>	CTCTA
A3_1151-F_147A02#5-T1G2P (820)	TGGAAGCCAAAT	-CATCA <mark>T</mark>	AT <mark>GTG</mark> G <mark>AG</mark> GA -	TGC <mark>T</mark> T <mark>C</mark> CG- <mark>A</mark>	TGACTGACCA-	GAGGCTAT-	A-GATCT-C	TG-CGGGG	- <mark>AGGAA</mark> G- <mark>T</mark>	CTTAA
C2_1151-F_147G01#A27-T1G2P (827)	TGGAGGCCAAAT	-CATCAATT	ATGTGGAAGAG	TGC <mark>TTC</mark> TG- <mark>A</mark>	TGACTGACCA-	GAG-CTATC	A-GATCT-C	CTGGCAGT <mark>G</mark> (G <mark>AGGAA</mark> GT- <mark>T</mark>	CCTTA
B7_1151-F_147B04#A14-T1G1R (812)	TGG-AGCCAAT-	-CATCA-TT	ATT <mark>GAA</mark> A	TGCTCC GA	TGACTGAC-A-	GAGCTAT-	A-GATCT-C	CTGCATG	- <mark>AGGA-</mark> GT-T	CTT
A32T_1151F_083F05#A32-T1G1R (817)	TGAGCAAT	r <mark>catca-</mark> tt <mark>/</mark>	AT <mark>GTGAAGA -</mark> -	TGCTTCTC-A	TGACTGAC-A-	GAG-CTAT-	AAGATCT-	TG-CAGGG	- <mark>AGA</mark> GTCT	CTTAA
NO_6_1151F_083E05#6-T1G1R (833)	TGAGCCAAAT	-CATCAATT	AT <mark>GTGA-GA</mark>	TGC <mark>T</mark> TC-GGA	TGACTGACCA-	GAG-CTAT-	AAGATCT-	TG-CAGTGAG	<mark>AGTC</mark> T	CTTAA
C8_1151-F_147G04#A35-T1G2R (815)	TGAGGCAAT-	-CATCA-TT	AT <mark>GTGA-GA</mark>	TGC <mark>TTCG</mark> A	TGACTGAC-A-	GAG-CTATT	A-GATCT-C	TGGCAGGG	- <mark>AGGAA</mark> GT - T	CTT
A7_1151-F_147A04#9-T1G2P (821)	TGGAAGCCAAAT	-CATCA T	ATGTGAAGA	TGC <mark>T</mark> T <mark>C</mark> CG- <mark>A</mark>	TGACTGACCA-	GAG-CTAT-	A-GATCT-C	TGCGTG	- <mark>A-GAA</mark> GTCT	CTT
B12_1151-F_147E06#A25-T1G2P (822)	TGGAAGCCAAAT	-CATCAAT-A	ATGTGAAGA-A	TGC <mark>TTC</mark> CG- <mark>A</mark>	TGACTGACCA-	GAG-CTATT	A-GATCT-C	TGGCAGTG-G	-AGGA- <mark>G</mark> TC <mark>T</mark>	CTT
A6_1151-F_147E03#8-T1G2R (824)	TGGAAGCCAAAT	-CATCATT-	ATGTGAAGAA-	TGC <mark>T</mark> TCCTGA	TGACTGAC-A-	GAG-CTAT-	A-GATCT-C	TG-CAGTG-G	-AGGAA <mark>G</mark> TC <mark>T</mark>	CTTTA
B4_1151-F_147F02#A11-T1G2R (828)	TGGAAGCCAAAT	CATCATT-	ATGTGAAGA-T	TGC <mark>TTC G</mark> A	TGACTGACCAA	GAG-CTATT	A-GATCT-C	TGGCAGTG-G	-AGGA- <mark>G</mark> TC <mark>T</mark>	CTT-A
A8_1151-F_147_E04#10-T1G2R (826)	TGGAAGCCAAAT	CATCAAT-	TGTGA-GAAT	TGCTTCCGG	TGACTGACCA -	GAGGCTATT	A-GATCT-C	TGGCAGTG-G	AGGAGGTCT	CTT
A11_1151-F_147A06-#13-T1G2R (831)	TG-AAGCCAAAT	CATCAATT	TGTGAAGA-T	TGCTTCCGG	TGACTGACCA-	GAG-CTATT	A-GATCTC	TGGCAGTG-G	AGGAAGTCT	CTTTA
B3_1151-F_147_B02#A6-T1G1R (836)	TGGAAGCCAAAT	CATCAATT	TGTGAAGAAT	TGCTTCCGGA	TGACTGACCA-	GAGGCTATT	A-GATCTT	TGGCAGTG-G	AGGAAGTCT	CTTTA
C12_1151-F_147F06#A41-T1G1P (837)	TGGAAGCCAAAT	CATCAATT	TGTGAAGAAT	TGCTTCCGGA	TGACTGACCAA	GAGGCTATT	AAGATCT-	TGGCAGTG-G	AGGAAGTCT	CTTTA
D3_1151-F_147D02#A50-T1G1P (829)		CATCAATT	TGTGAAGAAT	TGCTTCCGGA	TGACTGACCAA	GAGCTATT	AAGATCT-	TGGCAGTG-G	AGGAAGTCT	CTTTA
C10 1151-F 147 F05#A39-T1G2P (830)	TGGAAGCCAAAT	CATCAATT	TGTGAAGAAT	TGCTTCCGGA	TGACTGACCAA	GAGCTATT	AAGATCT-	TGGCAGTG-G	AGGAAGTCT	CTTTA
C3_1151-F_147_C02#A30-T1G1R (833)	TGGAAGCCAAAT	CATCAATT	TGTGAAGAAT	TGCTTCCGGA	TGACTGACCAA	GAGCTATT	AAGATCT-	TGCCAGTG-G	AGGAAGTCT	CTTTA
D8_1151-F_147_H04#A62-T1G1R (827)	TGGAAGCCAAAT	CATCAAT-	TGTGAAGAAT	TGCTTCCG-A	TGACTGACCA-	GAG-CTATT	A-CATCT-C	TGCCAGTG-G	AGA - GTOT	CTTTA
D2_1151-F_147_H01#A43-T1G1P (830)	TGGAAGCCAAAT	CATCAATT	TGTGAAGA-G	TGCTCCTCA	TGACTGACCA-	GAG-CTATT	AACATCT-	TG-CAGTG	ACCAACTCT	CTTTA
D5_1151-F_147D03#A55-T1G2R (828)	TGGAAGCCAAAT	CATCAATT	TGTGAAGAA-	TGCTTCCA	TGACTGAC-A-	GAG-CTATT	A-CATCT-C	TG-CAGTG-G		CTTTA
A9_1151-F_147A05#11-T1G2P (827)	TGGAAGCCAAAT	CATCAATT	TGTGAGGA	TGCTTCTG-A	TGACTGACCA-	CAG-CTATT	A-CATCTC	TGCCAGTC-G	AGGAAGTCT	CTTTA
B11_1151-F_147B06#A24-T1G2P (828)	TG-AAGCCAAAT	CATCAATT	ATGTGAGGA-T	TGCTTCCGGA	TGACTGACGA-	CACCTATT	A - CATCTT	TGCCAGTC-G	-AGGAAGTCT	CTTTA
B9_1151-F_147B05#A21-T1G1P (832)	TG-AAGCCAAAT	CATCAATT	TGTGAAGGAT	TGCTTCCGGA	TGACTGACCA -	GAG-CTATT	AACATCT-	TGCCAGTG-G	-AGGAAGTCT	CTTTA
B1_1151-F_147B01#A2-T1G1R (840)	TCCARCCARAT	CATCAATT	TCTCAACAAT	TGCTTCCGCA	TGACTGACCA-	CACCTATT	A-CATCT-C	TCCCACTC-C	ACCAACTCT	CTTTA
(
α β					v					
P										
(846)	846	.860	.870	.880	.890	.900	.910	.920	.930	942
B23 Exon-cDNA 885 bp (789)	AGTGGAAGCCAA	TTCATCAA	TATGTGAAGA	ATTGCTTCCC	GATGACTGAC	AGAGGCTA	TCAAGATC	CTGGCAGTGG	AGGAAGTCT-	CTTTA
B6_1151-F_147F03#A13-T2G2P (842)	AGTGGAAGCCAA	TTCATCAA	TATGTGAAGA	ATTGCTTCCC	GATGACTGAC	AGAGGCTA	TCAAGATC	CTGCCACTGC	GAAGTCT-	CTTTA
B8_1151-F_147F04#A15-T3G3P (825)	ACTCCA ACCCA A	TTCATCAA	TATCTCAACA	ATTCCTTCCT	CATCACTCAC	AGAGCTA			CAACTCT-	CTTTA
A10_1151-F_147D05#12-T2G1R (826)	AGTCGAAGCCAA	T-CATCAA	TATGTGAAGA	ATTGCTTCCC	GATGACTGAC	A-GAG-CTA	TCAAGATC	CTGCCACTGC	GAAGTCT-	CTTTA
A12_1151-F_147D06#16-T3G1P (828)	AGTCGAAGCCAA	T-CATCAA	TATGTGAAGA	ATTGCTTCCC	GATGACTGAC	A-GACCTA		CTGCCACTGC	AGAAGTCTT	CTTTA
B10_1151-F_147E05#A22-T3G3P (816)	ACTCCAACCCAA	T-CATCA-	TATGTGAGAA	TCCTTC	CATCACTCAC	A CACOCIA	P-CA-CATC	CTCCCACTCC	G-BACTCT-	
A34T_1151F_083G05#A34-T3G3P (826)	AGTCAGCCAA	TTCATCA -	TATCTCAACA	-TTCCTTC	CATCACTCAC-	-ACAC-CTA		CTG-CACTG-	AGAGTCT-	CTTAA
A42T 1151F 083 A07#A42-T3G2P (824)	ACTCCA ACCCAA	TTCATCA A	TATCTCAACA		CATCACTCAC	ACAC CTA			ACAACTCT-	CTTTA
D7_1151-F_147D04#A61-T3G3P (824)	ACTCCAACCAA	TCATCA -	TATCTCAACA	-TTGCTTCCC	CATGACTGAC		P-CA-GATC	CTGCCACTCC	AGGAGGTCT-	CTTTA
C1_1151-F_147C01#A26-T4G3P (831)	AGTCGAAGCCAA		TATCTCAACA	ATTACTTCCC	CATCACTCAC	AGAGGCTA	CARCATC	CTGCCACTCC		CTTTTA
D4_1151-F_147_H02#A53-T2G3P (831)	ACTCCAACCAA		TATOTOAAGA		CATCACTCAC	-CACCTA		CTGCCACTCC		CTTTTA
A5_1151-F_147A03#7-T2G3R (821)	-CTC-AACCAA	T-CATCA-	TATOTOAAGA		CATCACTGACC	-GAGOCIA	T-CA-CATC	CTGGCAGIGG	AGCA-GICI- AGAAGTTCT-	
B5_1151-F_147R03#A12-T3G2R (820)	-CTCCAACCAA	T-CATCA-	TATOTOA-GA		CATCACTGACC	-GAG-CTA	E-CA-CATC			
C4 1151-F 147 G02#A31-T2G3R (818)	-GIGGAAGCCAA		TATGIGAAGA		CATCACTGAC	-AGAGCTA	CA-GATC		AG-AAGICI- AGGAGTTCT-	
C6 1151-F 147 G03#A33-T3G3P (804)		CATCA	TATGTGAGGAGGA		CATGACTGAC	-CACCTA	CA-GATC	CTGGCAGGGG		
	CIOC ACCAAL	CHICK-	1110101000	100110	on one tone	and cin	- onlo		IC-	112

Fig. 1 (continued).

This might also reflect the frequent mutation propensity of NPM1 at the C-terminus (Fig. 1B). The identity of NPM1 with the consensus in the pT1 population was 66.4%, whereas it was 88.7% in the population with invasive tumor (pT2-4). The population gene identity in the group of pathological grade 1 was 70.5% and that in grades 2 and 3 was 87 and 89.5%, respectively. The overall gene identity in primary tumor in this cohort was 66.8%, while it was 88.3% in the population with recurrent tumors (Fig. 2). Furthermore, in shorter sequence comparison (restricted to 500 nucleotides), the sequence could be highly identical to the consensus sequence (up to 99.8%). The comparison can also be made to encompass the full cloning sequences (extended comparison). The trend of higher NPM1 sequence identity appearing in tumors of high malignancy was well preserved (Fig. 2). Bladder cancer with advanced tumor stage, higher tumor grade, and higher status of recurrence shows higher sequence identity to the consensus NPM1 cDNA. In this context, *NPM1* in bladder cancer acts more like a protooncogene. The integrity of *NPM1* shows increased probability of completion of tumor behavior. Accumulation of genetic variation results in defective malignancy potential and this can be seen in either tumor staging or grading pathologically and status of recurrence clinically. The concept of evaluating tumor behavior on a population basis in relevance to the sequence identity of a crucial cancer gene such as *NPM1* will give us a novel view in tumor genetics.

Discussion

Cancer is, in essence, a genetic disease [16]. Recent advances in biotechnology such as microarrays enable researchers to perform high-throughput comparisons of multiple genes between different biological settings or conditions. Thousands of genes with minor differences may be responsible for each




Fig. 2. *NPM1* identity at different sequence lengths. Using *NPM1* cDNA as the alignment profile, higher *NPM1* sequence identity in a population is consistent with poor tumor differentiation, advanced tumor stage, and likelihood of recurrence. This trend is seen in comparison to *NPM1* cDNA and well preserved at either restricted length (500 nucleotides) or extended comparison.

clinical variation. The concept may be straightforward in such divergent comparisons. Herein, we propose the convergent comparison of a gene in a population by its identity to the consensus sequence in different pathological and clinical settings. We suspect that a gene that might work with our hypothesis would be a pivotal gene involved in major cellular activity. *NPM1* is a transcription target of the proto-oncogene Myc [17]. NPM regulates the stability and transcriptional activity of p53 [9]. p53 has been linked to about half of human cancers and its mutation has prognostic implications in bladder cancers [18]. As a member of the nucleoplasmin family, NPM acts as a molecular chaperone that shuttles rapidly between nucleus and cytoplasm. With the diversity of its binding to many partners, it is involved in much more complex biological activity than expected.

One may expect that a tumor is the result of a genetic defect that causes cell cycle deregulation and escape from the surveillance of a tumor suppressor gene such as p53. One may also be interested in finding possible clues to identify subgroups in all cancer patients that will be more susceptible to treatment outcome and better prognosis. Falini et al. reported that mutation in the carboxy-terminus of *NPM1* causes encoding of abnormal proteins that are crucial for the nuclear export signal motif and nucleolar localization [19]. These mutants cause cytoplasmic localization of NPM. NPMc⁺ represents a subgroup of patients who have normal karyotype

and better prognosis. In fact, *NPM* exists in normal cells. Under proliferating or tumorigenesis conditions, *NPM* will overexpress in response to the proliferative process or oncogenic stress. Mutation in a pivotal gene and functional protein in cancer cells could be associated with better treatment response and prognosis.

It is well known that the strongest predictors in a clinical scenario are tumor stage and grade. In this study, using a finite alignment algorithm, the *NPM1* identity in a population correlates well with bladder tumor stage, grade, and recurrence status. Our data imply that the probability of *NPM1* mutation is an indicator of clinical relevance in bladder cancer. Most importantly, *NPM1* genetic changes evaluated on a population basis prove to be valuable and realistic in reflecting the pathological and clinical settings of cancer. *NPM1* is illustrated to be a crucial gene in cancer genetics.

Materials and methods

Total RNA was extracted using the Trizol method (Invitrogen). Fresh mRNAs were reverse transcribed to cDNA using M-MLV (Invitrogen). Both forward and reverse primers spanning the *NPM1* gene were analyzed to confirm the fidelity of sequence. The forward primer was 5'-GCAGCGTTCTTT-TATCTCCG-3', about 37 bp upstream of the transcription start site. The reverse primer was 5'-TAAAACCAAGCAAAGGGTGG-3', about 180 bp downstream of the transcription stop site. Primers were designed to encompass the full length of *NPM1* and for the fidelity of full-length sequencing of the gene. The consensus sequence used was from NCBI (NM_002520) with the *NPM1* as the profile, was performed using Vector NTI Suite 8 (InforMax).

Acknowledgments

This work was supported by Chang Gung Memorial Hospital Research Grant CMRPD150101 and National Sciences Council (ROC) Grant NSC95-2745-B-182-001-URD.

References

- Y. Yaginuma, et al., Genomic copy-number aberrations related to lymphnode metastasis of colon cancer, J. Int. Med. Res. 34 (2006) 390–396.
- [2] H.F. Mark, M. Samy, K. Santoro, S. Mark, D. Feldman, Fluorescent in situ hybridization study of c-myc oncogene copy number in prostate cancer, Exp. Mol. Pathol. 68 (2000) 65–69.
- [3] P. Nymark, et al., Identification of specific gene copy number changes in asbestos-related lung cancer, Cancer Res. 66 (2006) 5737–5743.
- [4] C. Cheng, R. Kimmel, P. Neiman, L.P. Zhao, Array rank order regression analysis for the detection of gene copy-number changes in human cancer, Genomics 82 (2003) 122–129.
- [5] C.D. Hurst, et al., High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization, Oncogene 23 (2004) 2250–2263.
- [6] X. Zhao, et al., An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays, Cancer Res. 64 (2004) 3060–3071.
- [7] A. Szebeni, M.O. Olson, Nucleolar protein B23 has molecular chaperone activities, Protein Sci. 8 (1999) 905–912.
- [8] M. Okuda, et al., Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication, Cell 103 (2000) 127–140.
- [9] E. Colombo, J.C. Marine, D. Danovi, B. Falini, P.G. Pelicci, Nucleophosmin regulates the stability and transcriptional activity of p53, Nat. Cell Biol. 4 (2002) 529–533.

- [10] S. Grisendi, C. Mecucci, B. Falini, P.P. Pandolfi, Nucleophosmin and cancer, Nat. Rev. Cancer 6 (2006) 493–505.
- [11] B. Falini, et al., ALK⁺ lymphoma: clinico-pathological findings and outcome, Blood 93 (1999) 2697–2706.
- [12] S. Schnittger, et al., Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype, Blood 106 (2005) 3733–3739.
- [13] B. Falini, et al., Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype, N. Engl. J. Med. 352 (2005) 254–266.
- [14] L. Dyrskjot, et al., A molecular signature in superficial bladder carcinoma predicts clinical outcome, Clin. Cancer Res. 11 (2005) 4029–4036.
- [15] K.H. Tsui, A.J. Cheng, P.L. Chang, T.L. Pan, B.Y. Yung, Association of

nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma, Urology 64 (2004) 839-844.

- [16] B. Vogelstein, K.W. Kinzler, Cancer genes and the pathways they control, Nat. Med. 10 (2004) 789–799.
- [17] K.I. Zeller, et al., Characterization of nucleophosmin (B23) as a Myc target by scanning chromatin immunoprecipitation, J. Biol. Chem. 276 (2001) 48285–48291.
- [18] J.G. Lorenzo-Romero, et al., Prognostic implications of p53 gene mutations in bladder tumors, J. Urol. 169 (2003) 492–499.
- [19] B. Falini, et al., Both carboxy-terminus NES motif and mutated tryptophan (s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc⁺ AML, Blood 107 (2006) 4514–4523.